A tumor-targeting nano-adjuvant for in situ vaccine based on ultrasound therapy  

作　　者：Linjie Cui Haochen Yao Fuxin Xue Jiali Sun Xitong Ren Mengfei Zheng Zhilin Liu Zhaohui Tang 

机构地区：[1]Key Laboratory of Polymer Ecomaterials,Changchun Institute of Applied Chemistry,Chinese Academy of Sciences,Changchun,China [2]School of Applied Chemistry and Engineering,University of Science and Technology of China,Hefei,China [3]Department of Hepatobiliary and Pancreatic Surgery,The First Hospital of Jilin University,Changchun,China [4]Key Laboratory of UV Emitting Materials and Technology,Northeast Normal University,Changchun,China

出　　处：《Aggregate》2024年第3期290-298,共9页聚集体（英文）

基　　金：Ministry of Science and Technology of China,Grant/Award Number:2022YFE0110200;Natural Science Foundation of Jilin Province,Grant/Award Number:20230101037JC;National Natural Science Foundation of China,Grant/Award Numbers:52203198,52025035。

摘　　要：Ultrasound-generated antigens combined with TLR7/8 agonists as adjuvants have demonstrated significant anti-tumor efficacy as an in-situ vaccine.However,the use of TLR7/8 agonists can cause severe inflammatory responses.In this study,we present a novel tumor-targeting nano-adjuvant termed aPDL1-PLG/R848 NPs,which are composed of aPDL1 antibody,Fc-III-4C peptide linker(Fc-linker)and poly(L-glutamic acid)-grafted-R848.Under ultrasound irradiation,antigen-presenting cells activate immune mechanisms in vivo under dual stimulation of in situ antigens and immune adjuvants.The strategy inhibits primary tumor growth and induces a strong antigen-specific immune memory effect to prevent tumor recurrence in vivo.This work offers a safe and potent platform for an in situ cancer vaccine based on ultrasound therapy.

关 键 词：IMMUNOTHERAPY in situ vaccine R848 nanoparticles TUMOR-TARGETING ultrasound therapy 

分 类 号：R730.5[医药卫生—肿瘤]